Cargando…
Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
As a conserved protein interaction module that recognizes and binds to acetylated lysine, bromodomain (BRD) contains a deep, largely hydrophobic acetyl lysine binding site. Proteins that share the feature of containing two BRDs and an extra-terminal domain belong to BET family, including BRD2, BRD3,...
Autores principales: | Fu, Lei-lei, Tian, Mao, Li, Xiang, Li, Jing-jing, Huang, Jian, Ouyang, Liang, Zhang, Yonghui, Liu, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467383/ https://www.ncbi.nlm.nih.gov/pubmed/25849938 |
Ejemplares similares
-
Selective BET bromodomain inhibition as an antifungal therapeutic strategy
por: Mietton, Flore, et al.
Publicado: (2017) -
BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
por: To, Kenneth K. W., et al.
Publicado: (2023) -
Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010) -
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1
por: Zhang, Zhenfeng, et al.
Publicado: (2016) -
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
por: Henssen, Anton, et al.
Publicado: (2013)